Patient-controlled Analgesic Pumps Market To Reach $656.5 Million By 2030

Patient-controlled Analgesic Pumps Market Growth & Trends

The global patient-controlled analgesic pumps market size is expected to reach USD 656.5 million by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. Patient-controlled Analgesic (PCA) pumps offer several advantages including fewer post-operative complications, improved quality of recovery, less sedation, and minimal use of medication. Also, PCA pumps are useful among patients that have a problem in taking oral medications. Thus, the rising adoption of the medical device among patients that are unable to take oral medications is expected to drive the market. In addition, the growing trend of home healthcare during the COVID-19 pandemic is also expected to propel market growth in the coming years.

Patient-controlled analgesic pumps have positive outcomes for the pediatric postsurgical population including increasing autonomy, simplifying pain relief in the postoperative period, and maintaining stable hemodynamics. Innovative PCA techniques such as PCRA, PCEA, and noninvasive forms of PCA have extended the options available for pain treatment and are estimated to have a positive impact on market growth. Advances in the pumps including variable-rate infusions that are calculated based on patient needs for analgesic along with improved patient monitoring are anticipated to enhance the use of such techniques during the forecast timeframe.

Rising cases of chronic pain disorders including cancer, rheumatoid arthritis, and fibromyalgia are anticipated to boost the market growth. For instance, as per the CDC, in 2019 around 20.4% of adults had chronic pain. Chronic pain increases with age and is highest among adults aged 65 and above. Hence, the rising occurrence of chronic pain among adults is anticipated to create robust growth opportunities in the market.

 Request a free sample copy or view report summary: Patient-controlled Analgesic Pumps Market Report

Patient-controlled Analgesic Pumps Market Report Highlights

• North America accounted for the largest revenue share in 2022. Increased healthcare awareness among individuals about pain management is anticipated to fuel the regional growth

• By type, the electronic segment accounted for the largest revenue share in 2022 owing to several benefits offered by electronic PCA

• By application, the oncology segment accounted for the largest revenue share in 2022 owing to high usage of patient-controlled analgesic pumps in managing sustained cancer pain

• The hospitals segment held the largest revenue share as hospital settings provide advanced treatment facilities and are equipped with technologically advanced medical devices

• The home care settings segment is projected to expand at the fastest CAGR of 7.1% over the forecast period.

Patient-controlled Analgesic Pumps Market Segmentation

Grand View Research has segmented the global patient-controlled analgesic pumps market based on type, application, end use, and region:

Patient-controlled Analgesic Pumps Type Outlook (Revenue, USD Million, 2018 - 2030)

• Electronic

• Mechanical

Patient-controlled Analgesic Pumps Application Outlook (Revenue, USD Million, 2018 - 2030)

• Diabetes

• Oncology

• Gastroenterology

• Hematology

• Others

Patient-controlled Analgesic Pumps End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centers

• Home Care Settings

Patient-controlled Analgesic Pumps Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List Of Key Players Patient-controlled Analgesic Pumps Market

• Baxter.

• B. Braun SE

• Smiths Group plc

• Fresenius SE & Co. KGaA

• BD

• ICU Medical, Inc.